FR3087448B1 - Lignee pdc modifiee pour secreter une cytokine - Google Patents

Lignee pdc modifiee pour secreter une cytokine Download PDF

Info

Publication number
FR3087448B1
FR3087448B1 FR1859773A FR1859773A FR3087448B1 FR 3087448 B1 FR3087448 B1 FR 3087448B1 FR 1859773 A FR1859773 A FR 1859773A FR 1859773 A FR1859773 A FR 1859773A FR 3087448 B1 FR3087448 B1 FR 3087448B1
Authority
FR
France
Prior art keywords
cytokine
secret
line modified
pdc line
pdc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR1859773A
Other languages
English (en)
Other versions
FR3087448A1 (fr
Inventor
Dalil Hannani
Joel Plumas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pdc Line Pharma
Francais du Sang Ets
Original Assignee
Pdc Line Pharma
Francais du Sang Ets
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1859773A priority Critical patent/FR3087448B1/fr
Application filed by Pdc Line Pharma, Francais du Sang Ets filed Critical Pdc Line Pharma
Priority to JP2021523162A priority patent/JP2022513584A/ja
Priority to BR112021007767-7A priority patent/BR112021007767A2/pt
Priority to PCT/EP2019/078845 priority patent/WO2020083974A1/fr
Priority to CN201980070013.7A priority patent/CN113302286A/zh
Priority to AU2019369137A priority patent/AU2019369137A1/en
Priority to US17/288,019 priority patent/US20210393688A1/en
Priority to CA3117404A priority patent/CA3117404A1/fr
Priority to KR1020217013070A priority patent/KR20210092201A/ko
Priority to EP19794953.0A priority patent/EP3870693A1/fr
Publication of FR3087448A1 publication Critical patent/FR3087448A1/fr
Application granted granted Critical
Publication of FR3087448B1 publication Critical patent/FR3087448B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/46449—Melanoma antigens
    • A61K39/464491—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

La présente invention concerne une lignée PDC (cellules dendritiques plasmacytoïdes) modifiée génétiquement pour secréter une cytokine, et son utilisation pour augmenter l'expansion de cellules spécifiques d'antigènes dans des immunothérapies.
FR1859773A 2018-10-23 2018-10-23 Lignee pdc modifiee pour secreter une cytokine Active FR3087448B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1859773A FR3087448B1 (fr) 2018-10-23 2018-10-23 Lignee pdc modifiee pour secreter une cytokine
KR1020217013070A KR20210092201A (ko) 2018-10-23 2019-10-23 사이토카인을 분비하기 위한 변형된 pdc 계통
PCT/EP2019/078845 WO2020083974A1 (fr) 2018-10-23 2019-10-23 Lignée pdc modifiée pour secréter une cytokine
CN201980070013.7A CN113302286A (zh) 2018-10-23 2019-10-23 用于分泌细胞因子的经修饰的pdc细胞系
AU2019369137A AU2019369137A1 (en) 2018-10-23 2019-10-23 Modified PDC line for secreting a cytokine
US17/288,019 US20210393688A1 (en) 2018-10-23 2019-10-23 Modified pdc line for secreting a cytokine
JP2021523162A JP2022513584A (ja) 2018-10-23 2019-10-23 サイトカインを分泌するように改変されたｐｄｃ株
BR112021007767-7A BR112021007767A2 (pt) 2018-10-23 2019-10-23 linhagem de pdc modificada para secretar uma citocina
EP19794953.0A EP3870693A1 (fr) 2018-10-23 2019-10-23 Lignée pdc modifiée pour secréter une cytokine
CA3117404A CA3117404A1 (fr) 2018-10-23 2019-10-23 Lignee pdc modifiee pour secreter une cytokine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1859773A FR3087448B1 (fr) 2018-10-23 2018-10-23 Lignee pdc modifiee pour secreter une cytokine

Publications (2)

Publication Number Publication Date
FR3087448A1 FR3087448A1 (fr) 2020-04-24
FR3087448B1 true FR3087448B1 (fr) 2023-10-13

Family

ID=65685600

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1859773A Active FR3087448B1 (fr) 2018-10-23 2018-10-23 Lignee pdc modifiee pour secreter une cytokine

Country Status (10)

Country Link
US (1) US20210393688A1 (fr)
EP (1) EP3870693A1 (fr)
JP (1) JP2022513584A (fr)
KR (1) KR20210092201A (fr)
CN (1) CN113302286A (fr)
AU (1) AU2019369137A1 (fr)
BR (1) BR112021007767A2 (fr)
CA (1) CA3117404A1 (fr)
FR (1) FR3087448B1 (fr)
WO (1) WO2020083974A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202014920D0 (en) * 2020-09-22 2020-11-04 Unikum Therapeutics Aps Methods for treating cancer and autoimmune and inflammatory diseases

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG49008A1 (en) 1993-03-05 1998-05-18 Cytel Corp Hla-a2.1 binding peptides and their uses
BR9302851A (pt) 1993-07-14 1995-04-25 Pereira Antonio Martins Unidade integrada para tratamento de tampas/rolhas para garrafas
EP0950103B1 (fr) 1996-11-20 2008-11-12 Yale University La survivine, proteine inhibant l'apoptose cellulaire, et sa modulation
AU4990999A (en) 1998-07-14 2000-02-07 Jenner Biotherapies, Inc. Survivin, and peptides thereof, as an anti-cancer vaccine
WO2000020445A2 (fr) 1998-10-02 2000-04-13 Ludwig Institute For Cancer Research Antigenes tumoraux et clones de lymphocyte t cytotoxique (ctl) isoles grace a un nouveau procede
KR20020011967A (ko) 1999-03-02 2002-02-09 에드워드 에이. 맥더모트, 주니어 ＭＡＧＥ 5, 8, 9 및 11의 ｃＤＮＡ 클로닝 및 이를이용한 암 진단 방법
DE19917195B4 (de) 1999-04-16 2006-09-28 Immatics Biotechnologies Gmbh Peptid zur Auslösung einer Immunreaktion gegen Tumorzellen, diese enthaltende pharmzeutische Zusammensetzungen, dessen Verwendungen, dafür codierende Nukleinsäure und diese Nukleinsäure enthaltender Expressionsvektor
US7157091B1 (en) 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
US7892559B2 (en) 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
FR2837837B1 (fr) 2002-03-28 2006-09-29 Roussy Inst Gustave Epitopes peptidiques communs a des antigenes d'une meme famille multigenique
FR2848565B1 (fr) 2002-12-16 2007-04-06 Ets Francais Du Sang Lignee de cellules dendritiques gen2.2
US20070104689A1 (en) 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
FR2891462B1 (fr) 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
CA2665568C (fr) 2006-10-04 2018-01-09 Janssen Pharmaceutica, N.V. Preparation de cellules presentant l'antigene artificielles inactivees et leur utilisation dans des therapies cellulaires
WO2009013848A1 (fr) 2007-07-24 2009-01-29 Panasonic Corporation Matériau d'électrode négative pour une batterie nickel-hydrogène, procédé de traitement de celui-ci, et batterie nickel-hydrogène
PT2113253E (pt) 2008-04-30 2010-06-15 Immatics Biotechnologies Gmbh Formulações novas de peptídeos associados a tumores que se ligam a moléculas de classe i ou ii do antígeno leucocitário humano (hla) para vacinas
FR2931163B1 (fr) 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
CA2767767A1 (fr) 2009-07-30 2011-02-03 Helmholtz-Zentrum Fuer Infektionsforschung Gmbh Compositions pour generer une reponse immune specifique d'un antigene
WO2015095572A1 (fr) 2013-12-19 2015-06-25 Abbvie Inc. Méthodes pour traiter des bénéficiaires de transplantation du foie
CN203647890U (zh) 2013-12-25 2014-06-18 深圳市奥沃医学新技术发展有限公司 一种用于多源放射治疗设备的局部关源装置
US10414810B2 (en) 2015-05-07 2019-09-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Double mutant survivin vaccine

Also Published As

Publication number Publication date
CN113302286A (zh) 2021-08-24
KR20210092201A (ko) 2021-07-23
JP2022513584A (ja) 2022-02-09
BR112021007767A2 (pt) 2021-08-03
EP3870693A1 (fr) 2021-09-01
FR3087448A1 (fr) 2020-04-24
WO2020083974A1 (fr) 2020-04-30
US20210393688A1 (en) 2021-12-23
CA3117404A1 (fr) 2020-04-30
AU2019369137A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
EA202091333A1 (ru) Способы активации, модификации и экспансии t-клеток для лечения рака и связанных с ним злокачественных заболеваний
AU2019378883A8 (en) Fusosome compositions for T cell delivery
MX2021000308A (es) Composiciones de fusosoma y usos de estas.
PH12019502897A1 (en) Flow cells
PH12019500868A1 (en) Blockchain smart contract updates using decentralized decision
MX2019011040A (es) Composiciones y metodos para potenciar la expresion genica.
MX2022002462A (es) Composiciones y métodos para la modificación de cll1.
DK1379671T3 (da) Fremgangsmåder til dyrkning af circovirus
MX2021004277A (es) Composiciones y metodos para expresar el factor ix.
CL2016003172A1 (es) Anticuerpos dirigidos contra cd127
GT201400302A (es) Celulas para producir iduronato-2-sulfatasa recombinante
MX2018012866A (es) Composiciones y metodos para generar anticuerpos basado en el uso de un locus potenciador de la expresion.
MX2021010670A (es) Receptores de antigeno quimerico dirigidos a cd19 y usos de los mismos en inmunoterapia.
MX2022001977A (es) Poblaciones de celulas t gamma delta t ex vivo.
FR3087448B1 (fr) Lignee pdc modifiee pour secreter une cytokine
MA44907A (fr) Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation
CL2021002141A1 (es) Anticuerpos claudina 6 y usos de los mismos.
FR3034420A1 (fr) Anticorps monoclonaux anti-cd303
MX2022006994A (es) Metodos para generar celulas madre hematopoyeticas.
CO2021011198A2 (es) Receptores de citocinas quiméricos constitutivamente activos
MX2018012629A (es) Diferenciacion de celulas madre pluripotentes a celulas de endodermo intestinal del intestino medio.
CO2019012871A2 (es) Métodos de cultivo celular para expresar proteínas con heterogeneidad reducida
ES2312607T3 (es) Identificacion y caracterizacion de genes.
MX2021008983A (es) Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
ATE406461T1 (de) Rna-bioassay

Legal Events

Date Code Title Description
PLFP Fee payment
PLSC Publication of the preliminary search report

Effective date: 20200424

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6